Page 9,	**line 3:**	Change "veal" to -- calf --;
	line 6:	"(O)" (second occurrence) to -- (filled circles) --;
	line 22:	Delete "action"; and
		After "mechanism" insert -- of action --.
Page 10,	**line 4:**	Change "codified" to -- coded for --; and
		After "MHC" insert -- gene --.
Page 13,	**heading:**	Correct the heading "CLAIMS" to read
		-- **WHAT IS CLAIMED IS:** --.

IN THE ABSTRACT:

Line 7: Delete "(fig. 2)".

IN THE CLAIMS:

Claims 1-9: Please cancel without prejudice or disclaimer.

Please amend claims 10-16 as indicated below:

10. (Amended) [The use of histocompatibility molecules] A method for preparation of [a] the pharmaceutical composition [for stimulation of the immune system and treatment of cancer pathologies] of claim 17, comprising extracting MHC molecules from at least two different animal tissue, serum or cell sources.

11. (Amended) [Use,] The method according to [point] claim 10, in which [such histocompatibility] MHC molecules of each container are [of] extracted from different [origin] species.

12. (Amended) [A process for the extraction of histocompatibility molecules according to one of the previous points, characterized in that it comprises the following steps:] The method of claim 10 further comprising homogenizing [the original material] said tissues, sera or cells in the presence of Nonidet P40[;], centrifuging the homogenate and separating the supernatant[;], and dialyzing the supernatant against PBS through membranes with a cutoff of at least 10 kDa.

13. (Amended) [A process] The method according to claim 12, wherein [such] said homogenization is carried out until cell lysis is substantially complete, and wherein 150 to 450 ml of PBS and 0.3 to 1.8% Nonidet P40 (v/v) are used for each 100 g of original material.

14. (Amended) A method for [stimulation of the immune system of an organism for] the treatment of cancer [pathologies, characterized in] comprising administering to [the organism a patient an effective amount of MHC molecules extracted from an animal [or human] tissue[s], serum or cell[s] source.

B1

15. (Amended) [A] The method according to claim [14] 16, [characterized in administering in sequence or alternately histocompatibility molecules of different origin] wherein said MHC molecules from different species are administered sequentially or alternately.

16. (Amended) [A] The method according to claim [15] 24, wherein [such histocompatibility] the two doses of MHC molecules [are obtained from tissues, cells or sera of] originate from a different species.

Please add new claims 17-24:

17. A pharmaceutical composition useful for the treatment of cancer comprising at least two containers, each comprising an effective amount of MHC molecules extracted from an animal tissue, serum or cell source different from that of the other container.

18. The pharmaceutical composition of claim 17, wherein the MHC molecules of each container originate from a different species.

B2

19. The pharmaceutical composition of claim 17, wherein said animal is a human.

20. The pharmaceutical composition of claim 17, wherein said tissue, serum or cell source is goat, calf or pig liver, or bovine red blood cell.

21. The pharmaceutical composition of claim 17, wherein said MHC molecule has a molecular weight above 10,000 daltons and is extracted from the tissue, serum or cell source with detergents.